WO2020086496A1 - Metal-organic frameworks for the removal of uremic toxins - Google Patents

Metal-organic frameworks for the removal of uremic toxins Download PDF

Info

Publication number
WO2020086496A1
WO2020086496A1 PCT/US2019/057302 US2019057302W WO2020086496A1 WO 2020086496 A1 WO2020086496 A1 WO 2020086496A1 US 2019057302 W US2019057302 W US 2019057302W WO 2020086496 A1 WO2020086496 A1 WO 2020086496A1
Authority
WO
WIPO (PCT)
Prior art keywords
metal
nodes
uremic toxins
sulfate
adsorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/057302
Other languages
French (fr)
Inventor
Omar K. Farha
Satoshi Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Priority to US17/286,986 priority Critical patent/US12403412B2/en
Publication of WO2020086496A1 publication Critical patent/WO2020086496A1/en
Anticipated expiration legal-status Critical
Priority to US19/289,512 priority patent/US20250360434A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/223—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material containing metals, e.g. organo-metallic compounds, coordination complexes
    • B01J20/226—Coordination polymers, e.g. metal-organic frameworks [MOF], zeolitic imidazolate frameworks [ZIF]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28057—Surface area, e.g. B.E.T specific surface area
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28078—Pore diameter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28078—Pore diameter
    • B01J20/2808—Pore diameter being less than 2 nm, i.e. micropores or nanopores
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28078—Pore diameter
    • B01J20/28083—Pore diameter being in the range 2-50 nm, i.e. mesopores
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption

Definitions

  • Uremic toxins are generally divided into several groups based on their physical and/or chemical properties. Uremic toxins comprised of the solutes that are bound to the transport human serum albumin (HSA) in human blood are called protein-bound toxins (PBTs). (See, e.g., Vanholder, R., et al., Kidney Int 2003, 63 (5), 1934-43.) PBTs bind to several adsorption sites on HSA by electrostatic interaction and/or van der Waals forces.
  • HSA human serum albumin
  • PBTs protein-bound toxins
  • PBT is poorly removed through conventional extracorporeal renal replacement therapies by diffusion, such as hemodialysis.
  • Activated carbon zeolites and composite membranes have been reported as adsorbents to remove uremic toxins. These are mainly porous materials which can adsorb the uremic toxins into their pores; however, a uremic toxin adsorbate with high selectivity and fast kinetics has not yet been achieved.
  • FIGS. 1A-1H show the structure of (FIG. 1A) a Zre node, (FIG. 1B) the organic linkers for UiO-66, UiO-67 and UiO-NDC metal-organic frameworks (MOFs), (FIG. 1C) the organic linker for MOF-808, (FIG. 1D) the organic linker for NU-1000 and NU-901, (FIG. 1E) the organic linker for PCN-608-OH, (FIG. 1G) the organic linker for NU-1200, and (FIG. lH(i)-(v)) Zr 6 -based MOF topologies.
  • FIGS. 1A-1H show the structure of (FIG. 1A) a Zre node
  • FIG. 1B the organic linkers for UiO-66, UiO-67 and UiO-NDC metal-organic frameworks (MOFs)
  • FIG. 1C the organic linker for MOF-808
  • FIG. 1D the
  • FIG. 1 is a graph of the percentage of p-cresyl removed from a sample by a Zre- based MOF.
  • FIGS. 3A and 3B show a general view and adsorption sites on NU-1000 before p- cresyl sulfate adsorption.
  • FIG. 3C depicts an optimized geometry of /;-cresyl sulfate-pyrene and a Zrr, node system after /;-cresyl sulfate adsorption (one orientation of /;-cresyl sulfate is extracted).
  • FIG. 4A is a graph showing the percentage of uremic toxin removal as a function of time at 297 K in water for three different uremic toxins.
  • FIG. 4B shows the chemical structures of the uremic toxins.
  • FIG. 5A shows adsorption isotherms of p-cresyl sulfate on NU-1000 at 297, 303, and 310 K.
  • FIG. 5B shows adsorption isotherms of indoxyl sulfate on NU-1000 at 297, 303, and 310 K.
  • FIG. 5C shows adsorption isotherms of hippuric acid on NU-1000 at 297, 303, and 310 K.
  • the dashed line in each graph represents the isotherms replicated by the
  • FIG. 6A is a graph of the percentage of p-cresyl sulfate adsorbed on HSA.
  • FIG. 6B shows an adsorption isotherm of p-cresyl sulfate on HSA.
  • Ci the initial concentration of p-cresyl sulfate.
  • FIG. 7A is a graph of the predicted fraction of adsorbed /;-cresyl sulfate adsorbed by NU-1000.
  • FIG. 7B shows the results of a study of the adsorptio of /;-cresyl sulfate and HSA by NU-1000 at 310 K in an aqueous solution of 0.9% NaCl.
  • FIGS. 8A-8F show N2 isotherms at 77 K and density functional theory (DFT)- calculated pore size distributions for Zr6-MOFs.
  • FIGS. 8A and 8B are for UiO-66, UiO-67, and UiO-NDC.
  • FIGS. 8C and 8D are for NU-1000, NU-1010, and PCN-6O8-OH.
  • FIGS. 8E and 8F are for MOF-808, NU-901, and NU-1200.
  • FIGS. 9A-9D depict the optimized geometry of NU-l000-/>-cresyl sulfate.
  • FIG. 9A shows the distance of /;-cresyl sulfate to the phenyl group of pyrene in site 1.
  • FIG. 9B depicts the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 1.
  • FIG. 9C shows the distance of / cresyl sulfate to the phenyl group of pyrene in site 2.
  • FIG. 9D depicts the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 2.
  • FIGS. 10A-10D depict the optimized geometry of NU-lOOO-indoxyl sulfate.
  • FIG. 10A shows the distance of indoxyl sulfate to the phenyl group of pyrene in site 1.
  • FIG. 10B shows the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 1.
  • FIG. 10C shows the distance of the /i-indoxyl sulfate to the phenyl group of pyrene in site 2.
  • FIG. 10D depicts the distance of oxygen-oxygen from on the Zm-node to the sulfonyl group in site 2.
  • FIGS. 11A-11D depict the optimized geometry of NU-lOOO-hippuric acid.
  • FIG. 11 A shows the distance of indoxyl sulfate to the phenyl group of pyrene in site 1.
  • FIG. 11B shows the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 1.
  • FIG. 11C shows the distance of /i-indoxyl sulfate to the phenyl group of pyrene in site 2.
  • FIG. 11D shows the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 2
  • FIG. 12 is a comparison of the linker structure, the number of adsorption sites, and the removal efficiency for /i-crcsyl sulfate by three esq -net MOFs.
  • FIGS. 13A and 13B show N2 isotherms at 77 K and the DFT-calculated pore size distribution before and after /i-crcsyl sulfate adsorption on NU-1000.
  • Brunauer-Emmett- Teller (BET) surface area decreased from 2180 m 2 /g to 1860 m 2 /g.
  • FIGS. 13C and 13D show the N2 isotherms at 77 K and DFT-calculated pore size distribution before and after indoxyl sulfate adsorption on NU-1000. The surface area decreased from 2180 m 2 /g to 1520 m 2 /g.
  • 13E and 13F show N2 isotherms at 77 K and DFT-calculated pore size distribution before and after hippuric acid adsorption on NU-1000.
  • the BET surface area decreased from 2180 m 2 /g to 1250 m 2 /g.
  • FIG. 14 shows the results of recyclability testing of NU-1000 for /i-crcsyl sulfate removal from water.
  • FIGS. 15A-15D show Langmuir plots or Freundlich plots for the adsorption of uremic toxins on NU-1000 at 297, 303, 310 K.
  • FIGS. 15A and 15B show Langmuir plots or Freundlich plots for uremic toxins on NU-1000 at 297, 303, 310 K for /i-crcsyl sulfate.
  • FIG. 15C shows Langmuir plots or Freundlich plots for uremic toxins on NU-1000 at 297, 303, 310 K for indoxyl sulfate.
  • FIG. 15D shows Langmuir plots or Freundlich plots for uremic toxins on NU-1000 at 297, 303, 310 K for hippuric acid. The adsorption isotherm of /2-cresyl sulfate was fitted by the Freundlich equation model at 310 K (FIG. 11B). The dashed lines exhibit the isotherms replicated by the Langmuir parameters or Freundlich parameters in Table 1. [0019] FIG.
  • panels (a) - (d) shows ITC thermograms (panels (a) and (c)) and integrated heat data (panels (b) and (d)) for p-cresyl sulfate (panels (a) and (b)) and indoxyl sulfate (panels (c) and (d)) adsorption onto NU-1000
  • FIG. 17, panels (a) and (c) depicts isothermal titration calorimetry (ITC) thermograms for (FIG. 17, panel (a)) / -cresyl sulfate (/ CS) and (FIG. 17, panel (c)) indoxyl sulfate (IS) adsorption onto human serum albumin.
  • ITC isothermal titration calorimetry
  • FIG. 17, panels (a) and (c) depicts isothermal titration calorimetry (ITC) thermograms for (FIG. 17, panel (a)) / -cresyl sulfate (/ CS) and (FIG. 17, panel (c)) indoxyl sulfate (IS) adsorption onto human serum albumin.
  • ITC isothermal titration calorimetry
  • FIG. 18A shows that the plot of AH vs. AH, ionization for ITC thermograms collected in different buffers shows no correlation.
  • FIG. 18B shows that enthalpy and entropy compensation was observed during the adsorption of p-CS onto NU-1000.
  • FIG. 19 shows the temperature dependence of the binding association constant (Ka) for the adsorption of uremic toxins onto NU-1000.
  • FIG. 20 shows the temperature dependence of the overall binding association constant (Ka) for the adsorption of uremic toxins onto HSA.
  • FIG. 21, panels (a) and (c) depicts ITC thermograms for p-C adsorption onto (FIG. 21, panel (a)) NU-1010 and (FIG. 21, panel (c)) PCN-608-OH.
  • the corresponding integrated heat data fit with a single-site model (black line).
  • FIGS. 22A and 22B show a comparison of AH, TAS and AG values for (FIG.
  • MOFs for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples taken from patients suffering from a uremia-related disease, such as chronic kidney failure.
  • MOFs are hybrid, crystalline, porous compounds made from metal-ligand networks that include inorganic nodes connected by coordination bonds to organic linkers.
  • the inorganic nodes or vertices in the framework are composed of metal ions or clusters.
  • the inorganic nodes may have 6 metal atoms.
  • Such a node is represented herein as an Me node.
  • the MOFs used in the methods described herein are water-stable, highly porous structures with high surface areas and p-conjugation in their organic linkers, which enables them to undergo p-p binding interactions with uremic toxins.
  • the organic linkers include pyrene groups or biphenyl groups.
  • the MOFs also desirably have hydroxyl groups on their metal nodes, which enable adsorption of uremic toxins by electrostatic interactions.
  • Non-limiting examples of MOFs that can be used for the absorption of uremic toxins include NU-1000, NU-901, NU-1010, and isostructural MOFs having different metal atoms, such as, but not limited to, Hf atoms, at their nodes.
  • NU-1000 is a zirconium-based MOF having Zrc nodes connected by tetratopic
  • NU-1000 has a esq network topology. More details regarding the structure ofNU-lOOO and methods for its synthesis can be found in Mondloch, et ah, J. Am. Chem. Soc. 135, 10294_10297 (2013). Hf- NU-1000 is a MOF that has Hfi, nodes, rather than Zre nodes, but is otherwise isostructural with NU-1000. More details regarding the structure of Hf-NU-lOOO and methods for its synthesis can be found in Beyzavi et ah, J. Am. Chem. Soc. 2014, 136, 45, 15861-15864.
  • NU-901 is a zirconium-based MOF having Zrc nodes connected by TBAPy linkers.
  • NU-1000 has a scu network topology. More details regarding the structure of NU- 901 and methods for its synthesis can be found in Chem. Mater. 2013 25 (24) 5012-5017.
  • NU-1010 is a zirconium-based MOF having Zre nodes connected by tetratopic
  • NU-1010 has a esq network topology. More details regarding the structure ofNU-lOlO and methods for its synthesis can be found in the Examples, below.
  • isostructural hafnium MOFs, cerium MOFs, and thorium MOFs can be synthesized using hafnium salts, cerium salts, and thorium salts, respectively.
  • hafnium salts, cerium salts, and thorium salts respectively.
  • the MOFs can be used as adsorbents to remove protein-bound uremic toxins (PBUTs) from samples containing one or more PBUTs by exposing the sample to the MOFs (e.g., by passing the sample over the MOFs), whereby the PBUTs are adsorbed by the MOFs.
  • the MOFs and their adsorbed uremic toxins can then be removed from the sample.
  • the adsorbed uremic toxins can then be separated from the MOFs, such that the MOFs can be recovered for re-use.
  • Removal of the uremic toxins can be achieved by exposing the MOFs to an acidic organic solution for a time and at a temperature sufficient to remove the uremic toxins, followed by a water wash.
  • a biological sample comprising blood or blood serum from a human dialysis patient can be used as the sample.
  • uremic toxins are toxic organic substances that accumulate in body fluids during the course of CKD and contribute to uremic syndrome.
  • PBUTs are bound to serum albumin proteins.
  • the uremic toxins may include aromatic rings with p-conjugation that enables them to undergo adsorption via p-p interactions with the linkers of the MOFs.
  • Examples of uremic toxins that can be removed using the MOFs include sulfate compounds, such as p- cresyl sulfate and indoxyl sulfate, and carboxylic acid compounds, such as hippuric acid.
  • the MOFs are particularly well suited for the removal of PBT uremic toxins, they can also be used to remove other types of water soluble uremic toxins, including water- soluble low-molecular-weight uremic toxins of the type described in Vanholder et al, Kidney International , Vol. 63 (2003), pp. 1934-1943.
  • a high percentage of the uremic toxins can be removed from a sample in a short time.
  • at least 20 mol. % of one or more uremic toxins are removed from a sample.
  • These high removal percentages can be achieved with exposure times of, for example, 10 minutes or less - including exposure times of five minutes or less and one minute or less.
  • This example illustrates the use of MOFs as an efficient adsorbent for uremic toxins.
  • FIG. 1A Nine kinds of Zr 6 -based MOFs with Zr6 nodes (FIG. 1A), but different linkers (FIGS. 1B - 1G), topology and connectivity were studied (FIGS. 1H-1L). These MOF materials were synthesized by following previously reported procedures. Furthermore, new MOF, NU-1010, esq net (4,8)-connected Zr6-MOF were synthesized. UiO-66, UiO-67, and UiO-NDC (FIG.
  • BDC l,4-benzenedicarboxylate
  • BPDC 4-dicarboxylate
  • NDC 2,6-naphthalenedicarboxylate linkers
  • NU-1000, NU-1010, and PCN-608-OH have 8-connected Zre nodes bridged by tetratopic linkers to give a esq topology net structure, TBAPy, TCPB, 3,3',5,5'-tetrakis(4- carboxyphenyl)-4,4'-dihydroxybiphenyl (TCPB-OH), respectively.
  • TCPB-OH 3,3',5,5'-tetrakis(4- carboxyphenyl)-4,4'-dihydroxybiphenyl
  • NU-901 contains the same linker and node as NU-1000, it yields a different topology (scu).
  • NU-1200 contains 8-connected Zre nodes bridged by 4',4"-(2,4,6- trimethylbenzene-l,3,5-triyl)tribenzoate (TMTB) linkers to give the topology net structure.
  • TMTB trimethylbenzene-l,3,5-triyl
  • MOF- 808 contains 6-connected Zre nodes bridged by l,3,5-trimesilate linkers to give spn topology. (See, e.g., Furukawa, FT, et al., J Am Chem Soc 2014, 136 (11), 4369-81.)
  • FIG. 2 shows the removal efficiency of / cresyl sulfate by the nine MOF materials in water at 297 K for 24 h at concentrations that simulate those in the blood of CKD patients.
  • NU-1000 offered the highest uptake, removing 98% of the / creysl sulfate in the solution.
  • an uptake of UiO-NDC (3.3 %) was found to be almost the same as that of UiO-66 (2.1 %) and UiO-67 (4.7 %), and an uptake of 6-connected MOF-808 (6.2 %) was found to be lower than some of the 8-connected MOFs (NU-1000, NU-901, NU-1010).
  • PCN-6O8-OH and NU-1200 exhibited lower uptakes than that of NU-1000, although these MOFs have the same esq topology and/or 8 connectivity, respectively.
  • NU-901 that contains a pyrene-based linker displayed the second highest uptake, following NU-1000. Although it has the smallest micro pore size of all MOF materials, it removed 86% of the / cresyl in the solution (Table 1).
  • the N2 isotherms and pore size distribution plots for the MOFs listed in Table 1 are shown in FIGS. 8A - 8F.
  • NU-1200 has a large pore size and a spacious site between linkers, the low uptake might be due to some steric repulsion between / crcsyl sulfate and the methyl group on the linker.
  • NU-1000, NU-1010, and PCN-608-OH have the same (4,8)-connected network with esq net, only NU-1000 exhibited the highest removal efficiency, reaching more than 98%.
  • NU-1010 had a smaller p-conjugated linker, and its efficiency decreased from 98% to 34%, possibly because of a weak p-p interaction with biphenyl and / cresyl sulfate on Site 2.
  • PCN-608-OH is substituted with a hydroxyl group on the 4,4’-position of biphenyl, and its uptake decreased from 34% to 10%, possibly due to steric impulsion of the hydroxyl group on the 4,4’-position (FIG. 12).
  • FIG. 4A shows the removal efficiency of uremic toxins by NU-1000 at 297 K as a function of time. Within only 1 min, NU-1000 removed more than 70 % of the / cresyl sulfate in the solution. This rapid uptake can be attributed to the large pore aperture size and pore volume of NU- 1000 facilitating the diffusion of the /;-cresyl sulfate. In addition, the uptakes of indoxyl sulfate and hippuric acid reached more than 98% in 1 min, indicating that there might be a stronger interaction between these two adsorbates and NU-1000.
  • FIGS. 5A-5C The type-I adsorption isotherms of uremic toxins in NU-1000 are shown in FIGS. 5A-5C. After the adsorption at 1.0 mM of /;-cresyl sulfate, the pore size distribution of large hexagonal mesopores in N2 isotherms at 77 K were slightly shifted from 29.5 A to 27.3 A, and the BET surface area decreased from 2140 m 2 /g to 1860 m 2 /g, which might be due to the adsorption of / cresyl sulfate in NU-1000 (FIGS. 13A and 13B).
  • Adsorption capacity on a mole basis a, b and c were calculated by Langmuir equation.
  • FIG. 6A shows the percentage of adsorbed p-crcsyl sulfate on HSA.
  • the average value was found to be 82 ⁇ 5% at the initial concentration (G) range of 0.01 to 0.1 mM.
  • the Freundlich model offers the best fit for p-crcsyl sulfate adsorption on HSA at 310 K as well as on NU-1000.
  • the Freundlich parameters are summarized in Table 3.
  • NU-1000 displayed the higher uptake per gram of p-crcsyl sulfate in mg of NU- 1000 and larger KF than that of FISA when compared to the adsorption uptakes (mg g 1 ).
  • FIG. 7 A shows the predicted removal fraction of y>-cresyl sulfate from HSA using MU- 1000.
  • MHSA 50 mg
  • MNU-IOOO 2.5, 10, 20,
  • MOF-808 were prepared according to literature procedures. (See, e.g., Katz, M. J., el al., Chem. Commun. 2013, 49, 9449-9451; Mondloch, J. E., et al, Nat Mater 2015 , 14 (5), 512-6; Pang, J., et al, J. Am. Chem. Soc. 2017, 139 (46), 16939-16945; Liu, T.-F., et al, Eur. J. Inorg. Chem. 2016, 27, 4349-4352; and Furukawa, H., et al, J Am Chem Soc 2014, 136 (11), 4369-81.)
  • Powder X-ray diffraction (PXRD) patterns were collected on an ATX-G (Rigaku) instrument equipped with an 18 kW copper rotating anode X-ray source. Roughly 3 mg of sample was loaded onto a sample holder and mounted on the instrument. Samples were recorded from 2° ⁇ Q ⁇ 20° at a scan rate of 27min and a step size of 0.05.
  • N 2 sorption isotherms were collected on a Micromeretics Tristar II 3020 instrument at 77 K. Prior to the measurement, the samples were activated on a SmartVacPrep port by heating at the desired temperature under a vacuum overnight. Pore size distributions were calculated from the adsorption isotherms using the DFT method, based on a molecular statistical approach.
  • HPLC measurements were performed by an Agilent HPLC 1100 system equipped with a binary pump, a column thermostat, an auto sampler, and a diode-array absorbance detector (DAD), using an Ascentic C18 HPLC column (5 pm particle 150 mm> ⁇ 4.6 mm I.D.).
  • a reverse phase HPLC assay of / cresyl sulfate was carried out using an isocratic elution with a flow rate of 1.0 mL/min, a column temperature of 40 °C, a mobile phase of acetonitrile and water (35: 65% v/v), and a detection wavelength of 230 nm.
  • TCPB linker was synthesized according to literature procedures. (See, e.g., Pang, J., et al., J. Am. Chem. Soc. 2017, 139 (46), 16939-16945.) ZrCU (20 mg, 0.10 mmol) was dissolved in 3 mL dimethylformamide (DMF) and heated for lh at 80 °C, and subsequently trifluoroacetic acid (TFA) (100 pL, 1.31 mmol) was added and cooled down to room temperature before TCPB (10 mg, 0.059 mmol) was dissolved and sonicated for 15 min. The solution was heated at 120 °C for 48 hours. The white powder was washed three times with fresh DMF, acetone, and ethanol. The sample was activated by supercritical CO2 drying before being thermally activated in a vacuum oven at 80 °C for 18 hours.
  • DMF dimethylformamide
  • TFA trifluoroacetic acid
  • DFT calculations were conducted.
  • the geometry optimizations of >-cresyl and indoxyl sulfate were carried out in the Gaussian 16 package using the M06-L density functional and def2-SVP basis set.
  • the positions of the framework atoms were taken from the experimental crystal structures and fixed during the optimizations. Proper truncations of the distant atoms were made to reduce the system size while keeping the entire system charge neutral.
  • the proton topologies of the Zrc nodes were built according to a previous study. For the substrates, the positions of the sulfur atoms were also fixed to the experimental data, while the other atoms were added and allowed to move.
  • hippuric acid In the case of hippuric acid, the structure was built by replacing an adjacent pair of OH and OH2 groups on the node with the deprotonated hippuric acid through coordination between two Zr atoms and the carboxylate group. The geometry optimizations were performed as described above, with the entire hippuric acid not fixed and allowed to relax. Kinetic isotherm studies
  • Adsorption isotherm studies were conducted to calculate the maximum adsorption capacity of an adsorbent. These studies also give an understanding of the affinity of an adsorbent for target pollutants.
  • Adsorption isotherms were constructed by exposing 1.5 mg of NU-1000 to 2.5 mL of an aqueous water solution (or 0.9% NaCl solution) to a designated concentration of uremic toxins in 1.5-dram vials. The solution was placed in the oven at a designated temperature (297, 303, 310 K) for 24 hours to reach saturation uptake. After 24 hours, the sample was filtered with a 0.45 pm PVDF filter syringe. The initial and equilibrium concentrations were measured by using an Agilent HPLC 1100, and the amount of uremic toxins uptake Q in mg of uremic toxins per gram of MOF was determined at each point according to Eq. 6:
  • Adsorption isotherm studies were performed by exposing 50 mg of HSA to 1.0 mL of an aqueous 0.9% NaCl solution to a designated concentration of / crcsyl sulfate in 1.5-dram vials. The solution was placed in the oven at 310 K oven for 24 hours to reach saturation uptake. After 24 hours, the sample was filtrated and centrifuged at 1500 rpm for 15 min to allow the MOF to be settled by an ultrafiltration device (ultracel PL membrane, 30 Da, Millipore Sigma). The initial and equilibrium concentrations were measured by using an Agilent HPLC 1100, and the amount of uremic toxins uptake Q in mg of uremic toxins per gram of MOF was determined at each point, according to previous studies of uremic toxins.
  • Facile regeneration of an adsorbent is very important not only for its
  • NU-1000 could be activated with a 0.5 mM HC1/DMF solution for 10 hours at 80 °C, followed by a water wash (10 mL c 5 times), and the regenerated NU-1000 could be reused for the next adsorption.
  • adsorption-desorption cycles can be successfully repeated three times, and the same high removal efficiency by the regenerated NU-1000 can be obtained up to three times (FIG. 14).
  • Example 2 [0066] Example 1 describes the efficient removal of PBUTs by NU-1000, an 8-connected MOF consisting of Zre-nodes and tetratopic pyrene-based linkers.
  • This Example describes the use of ITC to identify the type and quantify the thermodynamic parameters of adsorptive interactions between PBUTs, namely p-CS and IS, and mesoporous Zr-based MOFs.
  • the number of injections 58 58 29 29 29 29 Injection volume (m ⁇ ) 5 5 10 10 10 10 Duration of each 10 10 20 20 20 20 20 injections (sec) Spacing between 500 500 500 500 500 500 500 injections (sec)
  • NU-1000 exhibited positive values of TAS for p- CS adsorption, which contributed to the large Gibbs free energy change (AG).
  • thermodynamic data corresponded well to the previously observed SCXRD data, which revealed hydrogen bonding interactions between p- CS and hydroxyl ligands on the Zre-nodes of NU-1000 and p-p stacking (hydrophobic interactions) between p- CS and the framework’s pyrene linkers.
  • the binding affinity (K a ) of p- CS adsorbing onto NU-1000 decreased from 1.03 to 0.51 x 10 4 M 1 ; however, the binding affinity of indoxyl sulfate adsorbing onto NU-1000 remained constant at -1.0 c 10 4 M 1 (FIG. 19).
  • the entropy change associated with p- CS adsorption also decreased with increasing temperature from 1.29 kcal mol 1 to 0.99 kcal mol likely due to a weakening of p-p interactions between p- CS and the pyrene linkers of NU- 1000.
  • Example 1 reported two crystallographically distinct uremic toxin adsorption sites in NU-lOOO, Site 1 and Site 2. Specifically, in the large hexagonal mesopore (Site 1 ). / -CS sits perpendicular to the linker’s pyrene core while interacting with the phenyl substituent of one of the linker’s arms. While in the triangular small pore (Site 2), p-CS lies parallel to the pyrene region and interacts with two neighboring pyrene linkers. These observations led to the questioning of which site interacted more strongly.
  • thermodynamic parameters show that adsorption at Site 1 is entropically driven and due to hydrophobic interaction; the large increase in entropy compensates for the much smaller enthalpy change in the overall Gibbs free energy change.
  • adsorption at Site 2 is both entropically and enthalpically driven, arising from hydrophobic interactions and p-p interactions with the pyrene moiety of the linker.
  • PVDF membrane 0.45 pm, Satorious Minisart Syringe Filter
  • the solution was heated at 120 °C for 72 h. After cooling down to room temperature, white material was isolated by centrifugation (10 min, 1000 RCF) and washed with fresh DMF (15 mL each, three times) (soaked ⁇ l h between washes). The resulting white powder was suspended in 10 mL DMF and 0.3 mL of 12 M aqueous HC1 was added. The mixture was heated in an oven at 100 °C for 18 h. The white powder was washed with fresh DMF (15 mL each, three times), acetone (15 mL each, three times) and ethanol (15 mL each, three times). The sample was activated by supercritical CO2 drying before being thermally activated on a Smart VacPrep under ultrahigh vacuum at 80 °C for 18 h.
  • TPCB-OH linker was synthesized according to literature procedure. (Pang, et al., 2017.) ZrCL (20 mg, 0.10 mmol) was dissolved in 2.5 mL DMF and heated for 1 h in a preheated oven at 80 °C, and subsequently TFA (100 pL, 1.31 mmol) was added and cooled down to room temperature before TPCB-OH (10 mg, 0.015 mmol) was dissolved and sonicated for 15 min. The solution was heated at 120 °C for 72 h.
  • the material was isolated by centrifugation (10 min, 1000 RCF) and washed with fresh DMF (15 mL each, three times) (soaked ⁇ l h between washes).
  • the resulting powder was suspended in 10 mL DMF, and 0.3 mL of 12 M aqueous HC1 was added.
  • the powder was washed with fresh DMF (15 mL each, three times), acetone (15 mL each, three times), and ethanol (15 mL each, three times).
  • the sample was thermally activated on a Smart VacPrep under ultrahigh vacuum at 80 °C for 18 h.
  • ITC has been widely used for studying enzymatic systems but it should also be applicable to MOF systems.
  • the theory of ITC and the mathematical formulation behind it is briefly explained. Following the framework described in Lawrence Indyk et al., the binding of a single ligand, L (sulfate anion in this study), with a MOF receptor, M (MOF crystals in this study), can be considered (Indyk, L. et al., Methods Enzymol. 1998, 295, 350-364.):
  • Eqs. 12 and 13 can be extended to any binding system of ligands, noting that [MT] and [LT] are the total concentrations of MOF and ligand in the calorimeter cell. These variables are used because they are the known quantities in an experiment, and it would be useful to solve for some of the unknown quantities, such as [M] and [L] in terms of these two.
  • the dependent variable in ITC experiments is the total amount of heat released per injection of ligand, dQ: (Eq. 14) where V is the volume of the calorimetric cell, AH is the enthalpy of binding for formation of [ML] Substituting Eqs. 11-13 into Eq. 14 allows AQ to be written explicitly in terms of K a .
  • the integrated heats from each injection can be fit to a model as a function of molar ratio to determine heat from the standard parameters (K a , AH, and ri) in a single experiment.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronic kidney failure.

Description

METAL-ORGANIC FRAMEWORKS FOR THE REMOVAL OF UREMIC TOXINS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. provisional patent application number 62/749,353 that was filed October 23, 2018, the entire contents of which are incorporated herein by reference.
BACKGROUND
[0002] The accumulation of uremic toxins induces various uremia-related complications in patients with chronic kidney disease (CKD). Uremic toxins are generally divided into several groups based on their physical and/or chemical properties. Uremic toxins comprised of the solutes that are bound to the transport human serum albumin (HSA) in human blood are called protein-bound toxins (PBTs). (See, e.g., Vanholder, R., et al., Kidney Int 2003, 63 (5), 1934-43.) PBTs bind to several adsorption sites on HSA by electrostatic interaction and/or van der Waals forces. (See, e.g., Yu, S., et al., RSC Advances 2017, 7 (45), 27913- 27922.) Therefore, PBT is poorly removed through conventional extracorporeal renal replacement therapies by diffusion, such as hemodialysis. Activated carbon zeolites and composite membranes have been reported as adsorbents to remove uremic toxins. These are mainly porous materials which can adsorb the uremic toxins into their pores; however, a uremic toxin adsorbate with high selectivity and fast kinetics has not yet been achieved.
BRIEF DESCRIPTION OF THE DRAWINGS
[0003] Illustrative embodiments of the invention will hereafter be described with reference to the accompanying drawings, wherein like numerals denote like elements.
[0004] FIGS. 1A-1H show the structure of (FIG. 1A) a Zre node, (FIG. 1B) the organic linkers for UiO-66, UiO-67 and UiO-NDC metal-organic frameworks (MOFs), (FIG. 1C) the organic linker for MOF-808, (FIG. 1D) the organic linker for NU-1000 and NU-901, (FIG. 1E) the organic linker for PCN-608-OH, (FIG. 1G) the organic linker for NU-1200, and (FIG. lH(i)-(v)) Zr6-based MOF topologies.
[0005] FIG. 1 is a graph of the percentage of p-cresyl removed from a sample by a Zre- based MOF. [0006] FIGS. 3A and 3B show a general view and adsorption sites on NU-1000 before p- cresyl sulfate adsorption. FIG. 3C depicts an optimized geometry of /;-cresyl sulfate-pyrene and a Zrr, node system after /;-cresyl sulfate adsorption (one orientation of /;-cresyl sulfate is extracted).
[0007] FIG. 4A is a graph showing the percentage of uremic toxin removal as a function of time at 297 K in water for three different uremic toxins. FIG. 4B shows the chemical structures of the uremic toxins.
[0008] FIG. 5A shows adsorption isotherms of p-cresyl sulfate on NU-1000 at 297, 303, and 310 K. FIG. 5B shows adsorption isotherms of indoxyl sulfate on NU-1000 at 297, 303, and 310 K. FIG. 5C shows adsorption isotherms of hippuric acid on NU-1000 at 297, 303, and 310 K. The dashed line in each graph represents the isotherms replicated by the
Langmuir parameters in Table 1.
[0009] FIG. 6A is a graph of the percentage of p-cresyl sulfate adsorbed on HSA. FIG. 6B shows an adsorption isotherm of p-cresyl sulfate on HSA. Ci : the initial concentration of p-cresyl sulfate.
[0010] FIG. 7A is a graph of the predicted fraction of adsorbed /;-cresyl sulfate adsorbed by NU-1000. FIG. 7B shows the results of a study of the adsorptio of /;-cresyl sulfate and HSA by NU-1000 at 310 K in an aqueous solution of 0.9% NaCl.
[0011] FIGS. 8A-8F show N2 isotherms at 77 K and density functional theory (DFT)- calculated pore size distributions for Zr6-MOFs. FIGS. 8A and 8B are for UiO-66, UiO-67, and UiO-NDC. FIGS. 8C and 8D are for NU-1000, NU-1010, and PCN-6O8-OH. FIGS. 8E and 8F are for MOF-808, NU-901, and NU-1200.
[0012] FIGS. 9A-9D depict the optimized geometry of NU-l000-/>-cresyl sulfate. FIG. 9A shows the distance of /;-cresyl sulfate to the phenyl group of pyrene in site 1. FIG. 9B depicts the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 1. FIG. 9C shows the distance of / cresyl sulfate to the phenyl group of pyrene in site 2. FIG. 9D depicts the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 2.
[0013] FIGS. 10A-10D depict the optimized geometry of NU-lOOO-indoxyl sulfate. FIG. 10A shows the distance of indoxyl sulfate to the phenyl group of pyrene in site 1. FIG. 10B shows the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 1. FIG. 10C shows the distance of the /i-indoxyl sulfate to the phenyl group of pyrene in site 2. FIG. 10D depicts the distance of oxygen-oxygen from on the Zm-node to the sulfonyl group in site 2.
[0014] FIGS. 11A-11D depict the optimized geometry of NU-lOOO-hippuric acid. FIG.
11 A shows the distance of indoxyl sulfate to the phenyl group of pyrene in site 1. FIG. 11B shows the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 1. FIG. 11C shows the distance of /i-indoxyl sulfate to the phenyl group of pyrene in site 2. FIG. 11D shows the distance of oxygen-oxygen from on the Zre-node to the sulfonyl group in site 2
[0015] FIG. 12 is a comparison of the linker structure, the number of adsorption sites, and the removal efficiency for /i-crcsyl sulfate by three esq -net MOFs.
[0016] FIGS. 13A and 13B show N2 isotherms at 77 K and the DFT-calculated pore size distribution before and after /i-crcsyl sulfate adsorption on NU-1000. Brunauer-Emmett- Teller (BET) surface area decreased from 2180 m2/g to 1860 m2/g. FIGS. 13C and 13D show the N2 isotherms at 77 K and DFT-calculated pore size distribution before and after indoxyl sulfate adsorption on NU-1000. The surface area decreased from 2180 m2/g to 1520 m2/g. FIGS. 13E and 13F show N2 isotherms at 77 K and DFT-calculated pore size distribution before and after hippuric acid adsorption on NU-1000. The BET surface area decreased from 2180 m2/g to 1250 m2/g.
[0017] FIG. 14 shows the results of recyclability testing of NU-1000 for /i-crcsyl sulfate removal from water.
[0018] FIGS. 15A-15D show Langmuir plots or Freundlich plots for the adsorption of uremic toxins on NU-1000 at 297, 303, 310 K. FIGS. 15A and 15B show Langmuir plots or Freundlich plots for uremic toxins on NU-1000 at 297, 303, 310 K for /i-crcsyl sulfate.
FIG. 15C shows Langmuir plots or Freundlich plots for uremic toxins on NU-1000 at 297, 303, 310 K for indoxyl sulfate. FIG. 15D shows Langmuir plots or Freundlich plots for uremic toxins on NU-1000 at 297, 303, 310 K for hippuric acid. The adsorption isotherm of /2-cresyl sulfate was fitted by the Freundlich equation model at 310 K (FIG. 11B). The dashed lines exhibit the isotherms replicated by the Langmuir parameters or Freundlich parameters in Table 1. [0019] FIG. 16, panels (a) - (d), shows ITC thermograms (panels (a) and (c)) and integrated heat data (panels (b) and (d)) for p-cresyl sulfate (panels (a) and (b)) and indoxyl sulfate (panels (c) and (d)) adsorption onto NU-1000
[0020] FIG. 17, panels (a) and (c), depicts isothermal titration calorimetry (ITC) thermograms for (FIG. 17, panel (a)) / -cresyl sulfate (/ CS) and (FIG. 17, panel (c)) indoxyl sulfate (IS) adsorption onto human serum albumin. The corresponding integrated heat data (FIG. 17, panels (b) and (d)) fit with a single-site model (black line).
[0021] FIG. 18A shows that the plot of AH vs. AH, ionization for ITC thermograms collected in different buffers shows no correlation. FIG. 18B shows that enthalpy and entropy compensation was observed during the adsorption of p-CS onto NU-1000.
[0022] FIG. 19 shows the temperature dependence of the binding association constant (Ka) for the adsorption of uremic toxins onto NU-1000.
[0023] FIG. 20 shows the temperature dependence of the overall binding association constant (Ka) for the adsorption of uremic toxins onto HSA.
[0024] FIG. 21, panels (a) and (c), depicts ITC thermograms for p-C adsorption onto (FIG. 21, panel (a)) NU-1010 and (FIG. 21, panel (c)) PCN-608-OH. The corresponding integrated heat data (FIG. 21, panels (b) and (d)) fit with a single-site model (black line).
[0025] FIGS. 22A and 22B show a comparison of AH, TAS and AG values for (FIG.
22 A) p-CS and (FIG. 22B) IS adsorption onto NU-1000 and NU-1010 at 25 °C.
DETAILED DESCRIPTION
[0026] MOFs for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples taken from patients suffering from a uremia-related disease, such as chronic kidney failure.
[0027] MOFs are hybrid, crystalline, porous compounds made from metal-ligand networks that include inorganic nodes connected by coordination bonds to organic linkers. The inorganic nodes or vertices in the framework are composed of metal ions or clusters. For example, the inorganic nodes may have 6 metal atoms. Such a node is represented herein as an Me node. [0028] The MOFs used in the methods described herein are water-stable, highly porous structures with high surface areas and p-conjugation in their organic linkers, which enables them to undergo p-p binding interactions with uremic toxins. In some embodiments of the MOFs, the organic linkers include pyrene groups or biphenyl groups. The MOFs also desirably have hydroxyl groups on their metal nodes, which enable adsorption of uremic toxins by electrostatic interactions. Non-limiting examples of MOFs that can be used for the absorption of uremic toxins include NU-1000, NU-901, NU-1010, and isostructural MOFs having different metal atoms, such as, but not limited to, Hf atoms, at their nodes.
[0029] NU-1000 is a zirconium-based MOF having Zrc nodes connected by tetratopic
4,4',4'',4'"-(pyrene-l,3,6,8-tetrayl)tetrabenzoic acid (TBAPy) linkers. NU-1000 has a esq network topology. More details regarding the structure ofNU-lOOO and methods for its synthesis can be found in Mondloch, et ah, J. Am. Chem. Soc. 135, 10294_10297 (2013). Hf- NU-1000 is a MOF that has Hfi, nodes, rather than Zre nodes, but is otherwise isostructural with NU-1000. More details regarding the structure of Hf-NU-lOOO and methods for its synthesis can be found in Beyzavi et ah, J. Am. Chem. Soc. 2014, 136, 45, 15861-15864.
[0030] NU-901 is a zirconium-based MOF having Zrc nodes connected by TBAPy linkers. NU-1000 has a scu network topology. More details regarding the structure of NU- 901 and methods for its synthesis can be found in Chem. Mater. 2013 25 (24) 5012-5017.
[0031] NU-1010 is a zirconium-based MOF having Zre nodes connected by tetratopic
3,3',5,5'-tetrakis(4-carboxyphenyl)-l,r-biphenyl (TCPB) linkers. NU-1010 has a esq network topology. More details regarding the structure ofNU-lOlO and methods for its synthesis can be found in the Examples, below.
[0032] The descriptions above and the Examples below disclose the structures of, and methods of synthesizing and characterizing, Zr-based MOFs having various network topologies. However, it should be understood that, although the preceding description and the Examples focus on zirconium MOFs, other isostructural MOFs having the same network topologies can be made using the same methods by substituting the zirconium salts with salts of other metals in the synthesis. These isostructural MOFs differ from the Zr MOFs described herein with respect to the nature of the metal in the inorganic nodes. For example, isostructural hafnium MOFs, cerium MOFs, and thorium MOFs can be synthesized using hafnium salts, cerium salts, and thorium salts, respectively. These include MOFs that are isostructural with NU-1000, NU-901, and NU-1010, but that contain Hf6, Ce6, or Th6 nodes rather than Zre nodes.
[0033] The MOFs can be used as adsorbents to remove protein-bound uremic toxins (PBUTs) from samples containing one or more PBUTs by exposing the sample to the MOFs (e.g., by passing the sample over the MOFs), whereby the PBUTs are adsorbed by the MOFs. The MOFs and their adsorbed uremic toxins can then be removed from the sample.
Optionally, the adsorbed uremic toxins can then be separated from the MOFs, such that the MOFs can be recovered for re-use. Removal of the uremic toxins can be achieved by exposing the MOFs to an acidic organic solution for a time and at a temperature sufficient to remove the uremic toxins, followed by a water wash.
[0034] By way of illustration, in a dialysis process, a biological sample comprising blood or blood serum from a human dialysis patient can be used as the sample.
[0035] The uremic toxins are toxic organic substances that accumulate in body fluids during the course of CKD and contribute to uremic syndrome. PBUTs are bound to serum albumin proteins.
[0036] The uremic toxins may include aromatic rings with p-conjugation that enables them to undergo adsorption via p-p interactions with the linkers of the MOFs. Examples of uremic toxins that can be removed using the MOFs include sulfate compounds, such as p- cresyl sulfate and indoxyl sulfate, and carboxylic acid compounds, such as hippuric acid. Although the MOFs are particularly well suited for the removal of PBT uremic toxins, they can also be used to remove other types of water soluble uremic toxins, including water- soluble low-molecular-weight uremic toxins of the type described in Vanholder et al, Kidney International , Vol. 63 (2003), pp. 1934-1943.
[0037] Because the MOFs have high adsorption capacities for the uremic toxins, a high percentage of the uremic toxins can be removed from a sample in a short time. By way of illustration, in some embodiments of the methods, at least 20 mol. % of one or more uremic toxins are removed from a sample. This includes embodiments of the methods in which at least 50 mol. %, at least 60 mol. %, at least 80 mol. %, or at least 90 mol. % of one or more uremic toxins are removed from a sample. These high removal percentages can be achieved with exposure times of, for example, 10 minutes or less - including exposure times of five minutes or less and one minute or less. Methods for measuring the adsorption capacities of the MOFs are described in the Examples that follow. [0038] The values for any measured or measurable quantitative values recited herein whose values are temperature and/or pressure dependent refer to the values as measured at room temperature (~ 23 C) and/or atmospheric pressure (1 atm) unless otherwise indicated or readily understood.
EXAMPLES
Example 1
[0039] This example illustrates the use of MOFs as an efficient adsorbent for uremic toxins.
Result and discussion
Screening of Zr6 MOFs for /?-cresyl sulfate removal
[0040] Nine kinds of Zr6-based MOFs with Zr6 nodes (FIG. 1A), but different linkers (FIGS. 1B - 1G), topology and connectivity were studied (FIGS. 1H-1L). These MOF materials were synthesized by following previously reported procedures. Furthermore, new MOF, NU-1010, esq net (4,8)-connected Zr6-MOF were synthesized. UiO-66, UiO-67, and UiO-NDC (FIG. 1B) have l2-connected Zre nodes bridged by l,4-benzenedicarboxylate (BDC) linkers, biphenyl-4, 4-dicarboxylate (BPDC) linkers and 2,6-naphthalenedicarboxylate linkers (NDC), respectively. (See, e.g., Katz, M. J., et al, Chem. Commun. 2013, 49, 9449- 9451.) NU-1000, NU-1010, and PCN-608-OH have 8-connected Zre nodes bridged by tetratopic linkers to give a esq topology net structure, TBAPy, TCPB, 3,3',5,5'-tetrakis(4- carboxyphenyl)-4,4'-dihydroxybiphenyl (TCPB-OH), respectively. (See, e.g., Mondloch, J.
E., et al., Nat Mater 2015, 14 (5), 512-6; and Pang, J., et al., J Am. Chem. Soc. 2017, 139 (46), 16939-16945.) While NU-901 contains the same linker and node as NU-1000, it yields a different topology (scu). NU-1200 contains 8-connected Zre nodes bridged by 4',4"-(2,4,6- trimethylbenzene-l,3,5-triyl)tribenzoate (TMTB) linkers to give the topology net structure. (See, e.g., Liu, T.-F., et al, Eur. J. Inorg. Chem. 2016, 27, 4349-4352.) Furthermore, MOF- 808 contains 6-connected Zre nodes bridged by l,3,5-trimesilate linkers to give spn topology. (See, e.g., Furukawa, FT, et al., J Am Chem Soc 2014, 136 (11), 4369-81.)
[0041] FIG. 2 shows the removal efficiency of / cresyl sulfate by the nine MOF materials in water at 297 K for 24 h at concentrations that simulate those in the blood of CKD patients. At this concentration, of all MOF materials studied, NU-1000 offered the highest uptake, removing 98% of the / creysl sulfate in the solution. In contrast to the anticipated results, an uptake of UiO-NDC (3.3 %) was found to be almost the same as that of UiO-66 (2.1 %) and UiO-67 (4.7 %), and an uptake of 6-connected MOF-808 (6.2 %) was found to be lower than some of the 8-connected MOFs (NU-1000, NU-901, NU-1010). PCN-6O8-OH and NU-1200 exhibited lower uptakes than that of NU-1000, although these MOFs have the same esq topology and/or 8 connectivity, respectively. NU-901 that contains a pyrene-based linker displayed the second highest uptake, following NU-1000. Although it has the smallest micro pore size of all MOF materials, it removed 86% of the / cresyl in the solution (Table 1). The N2 isotherms and pore size distribution plots for the MOFs listed in Table 1 are shown in FIGS. 8A - 8F.
Table 1. N2 isotherms data and topologies of Zr6-MOFs
Surface area Micropore size
Adsorbent connectivity Topology Removal %
/ m2 g 1 / A
UiO-66 l685±25 15.9 12 feu 3
UiO-67 2505±15 23.4 12 feu 5
UiO-NDC l960±30 20.0 12 feu 4
PCN-608- 1910±15 29.5 8 esq 10
OH
NU-1010 l780± 5 29.5 8 esq 34
NU-1000 2l40± 5 29.5 8 esq 98
NU-901 2345± 5 12.0 8 scu 86
NU-1200 2105±10 21.6 8 the 10
MOF-808 1710±80 18.6 6 spn 15
Adsorption site analysis
[0042] To determine the adsorption sites of an aqueous / cresyl sulfate in NU-1000, a two-step process was constructed based on experimental crystallographic data and the computational method described in the experimental section. In the first step, single crystals of NU- 1000 were soaked in /;-cres l sulfate solution and examined through single crystal X- ray diffraction (SCXRD) analysis. In the second step, based on the SCXRD data, the stable structure of / cresyl sulfate was calculated by a DFT calculation process (see experimental section). As displayed in FIGS. 3A and 3B. /;-cres l sulfate molecules were adsorbed on two different adsorption sites of NU-1000 in the hexagonal meso pore (Site 1) and the triangle small pore (Site 2), sandwiched between two pyrene linkers. The average distances of oxygen-oxygen from on the Zre-node to the sulfonyl group in the triangle small pore and the hexagonal meso pore were 2.37 A. This provided evidence that / cresyl sulfate coordinated to the Zr6 node through hydrogen bonding (FIG. 3C). [0043] / crcsyl sulfate in the large hexagonal meso pore was vertically sited to a pyrene linker (Site 1). It also interacted with the phenyl group of the pyrene linker, and this distance suggests a p-p interaction (3.70 A). In contrast to Site 1. / crcsyl sulfate in the triangle small pore was sited parallel to the pyrene linker (FIG. 3C) and interacted with both of the faced pyrene linkers, at distances of 4.00 and 4.11 A, respectively (FIGS. 9A-9D). This demonstrated that there are two different adsorption sites in NU-1000. Similarly, the SCXRD analysis, using indoxyl sulfate as an adsorbate, indicated the same interaction behavior between indoxyl sulfate and the linker (FIGS. 10A-10D). These results give insight into not only the combined electrostatic interaction and p-p interaction, but also the topology that is important to capture / crcsyl sulfate. Without intending to be bound to any particular theory of the invention, it is proposed that the high / crcsyl sulfate uptake by NU-1000 was caused by highly hydrophobic adsorption sites sandwiched between two pyrene linkers and the hydroxyl group, which is capable of hydrogen bonding on Zre nodes. Therefore, 12- connected MOFs and MOF-808 may have offered low / crcsyl sulfate uptake because of an insufficiently p-conjugated system and/or lack of a hydroxyl group on the Zre nodes.
Although NU-1200 has a large pore size and a spacious site between linkers, the low uptake might be due to some steric repulsion between / crcsyl sulfate and the methyl group on the linker.
[0044] Although NU-1000, NU-1010, and PCN-608-OH have the same (4,8)-connected network with esq net, only NU-1000 exhibited the highest removal efficiency, reaching more than 98%. NU-1010 had a smaller p-conjugated linker, and its efficiency decreased from 98% to 34%, possibly because of a weak p-p interaction with biphenyl and / cresyl sulfate on Site 2. Moreover, PCN-608-OH is substituted with a hydroxyl group on the 4,4’-position of biphenyl, and its uptake decreased from 34% to 10%, possibly due to steric impulsion of the hydroxyl group on the 4,4’-position (FIG. 12).
Kinetic and adsorption isotherm studies
[0045] To understand the effect of uremic toxin structures on adsorption behavior, two more uremic toxins were selected as adsorbates: indoxyl sulfate and hippuric acid (FIG. 4B), for the purpose of comparison. These uremic toxins are PBTs. FIG. 4A shows the removal efficiency of uremic toxins by NU-1000 at 297 K as a function of time. Within only 1 min, NU-1000 removed more than 70 % of the / cresyl sulfate in the solution. This rapid uptake can be attributed to the large pore aperture size and pore volume of NU- 1000 facilitating the diffusion of the /;-cresyl sulfate. In addition, the uptakes of indoxyl sulfate and hippuric acid reached more than 98% in 1 min, indicating that there might be a stronger interaction between these two adsorbates and NU-1000.
[0046] The type-I adsorption isotherms of uremic toxins in NU-1000 are shown in FIGS. 5A-5C. After the adsorption at 1.0 mM of /;-cresyl sulfate, the pore size distribution of large hexagonal mesopores in N2 isotherms at 77 K were slightly shifted from 29.5 A to 27.3 A, and the BET surface area decreased from 2140 m2/g to 1860 m2/g, which might be due to the adsorption of / cresyl sulfate in NU-1000 (FIGS. 13A and 13B). Similarly, the pore size distribution and BET surface area were changed by the adsorption of indoxyl sulfate and hippuric acid as an adsorbate. The N2 isotherms and pore size distribution plots for the adsorption of indoxyl sulfate and hippuric acid are shown in FIGS. 13C-13F.
[0047] To further elucidate the effect of the structure of uremic toxins on adsorption behavior, adsorption isotherms in NU-1000 at 303 and 310 K were studied and are shown in FIGS. 5A-5C. Adsorption equilibrium data were calculated by the Langmuir equation and the Langmuir parameters. The Langmuir adsorption equilibrium constant (AT) and Langmuir adsorption capacity (Qmax) were determined from the transformed isotherms data and then summarized in Table 2. (See, e.g., Langmuir, I., J. Am. Chem. Soc. 1916, 38, 2221-2295.) The effect of temperature on adsorption capacity was also studied, and the KL values for / cresyl sulfate were determined to have decreased from 10.6 to 1.8 mM 1 at 297 K and 303 K, respectively. An almost linear adsorption isotherm was observed at 310 K. Furthermore, the Freundlich model gave the best fit for / cresyl adsorption isotherms at 310 K (R2 = 0.992) (FIGS. 15A-15D), indicating that the p-p interaction between NU-1000 and >-cresyl sulfate was weakened. (See, e.g., Freundlich, H., J. Phys. Chem. 1906, 57, 385-470.) In contrast to p- cresyl sulfate, the KL values for indoxyl sulfate increased slightly from 108 to 178 mM 1 upon increasing the adsorption temperature. This is more likely due to a consequence of strong p-p interaction between the indole and the pyrene linkers of NU-1000. This p-p interaction was investigated through SCXRD analysis (FIGS. 10A-10D). The KL values for hippuric acid increased drastically from 197 to 703 mM 1 upon increasing the temperature because hydroxyl on the Zr6-node/hippuric acid ligand exchange reaction was promoted by thermal energy as well as the SALI reaction. The stable structure of hippuric acid in NU-1000 was calculated by a DFT calculation process, assuming that the terminal carboxylic acid coordinated with the Zre (FIGS. 11A-11D). This analysis indicated that hippuric acid could interact with a pyrene linker as well as with / cresyl sulfate and indoxyl sulfate. These results of the adsorption isotherm analysis affirmed that Zrc based MOFs efficiently adsorbed both sulfate and carboxylic uremic toxins.
Table 2. Langmuir parameters for uremic toxins on NU-1000
Temperature / Qmax m g"1 NU- Qmax mol mol'1 NU-
Adsorbate KL mM 1 a
K c
_ WOO b 1000
297 10.6 166 1.24
-cresyl 303 1.8 440 3.30
sulfate
310
297 194 156 1.08
indoxyl 303 170 193 1.30
sulfate
310 189 254 1.71
hippuric 297 197 189 1.97
acid 303 506 182 1.82
310 703 199 1.88 a Langmuir adsorption equilibrium constant. b Adsorption capacity on a mass basis. c
Adsorption capacity on a mole basis a, b and c were calculated by Langmuir equation.
Removal of /?-cresyl sulfate from HSA
[0048] In the human plasma of CKD patients, about 80% of p-crcsyl sulfate was adsorbed and bound to HSA. The removal of p-crcsyl sulfate from HSA by NU-1000 was investigated. Firstly, to understand the adsorption behavior of HSA and p-crcsyl sulfate, adsorption isotherms were constructed in HSA to calculate the amount of adsorbed p-crcsyl sulfate. FIG. 6A shows the percentage of adsorbed p-crcsyl sulfate on HSA. The average value was found to be 82 ± 5% at the initial concentration (G) range of 0.01 to 0.1 mM. As shown in FIG. 6B, the Freundlich model offers the best fit for p-crcsyl sulfate adsorption on HSA at 310 K as well as on NU-1000. The Freundlich parameters are summarized in Table 3. In addition, NU-1000 displayed the higher uptake per gram of p-crcsyl sulfate in mg of NU- 1000 and larger KF than that of FISA when compared to the adsorption uptakes (mg g 1).
Table 3 Freundlich parameters of NU-1000 and HSA at 31 OK
_ Adsorbent _ KF 3 _ 1/n b
NU-1000 1.42 0.76
_ HSA _ 187 _ 0.97
3 Freundlich adsorption constant (unit: ((mg g_1)(L mg 1) 1 /n)
b the degree of nonlinearity and adsorption intensity of the adsorbents
[0049] The removal efficiency of -cresyl sulfate from HSA was predicted by comparing the predicted uptakes given by Freundlich parameters before the competitive adsorption in the presence of salt. From the given Freundlich parameters, each predicted uptake, QNU-IOOO and QHSA, can be described by Eq. 1 and Eq. 2, respectively.
Qe, NU-iooo (rng g 1) - 251 x C0·92 (Eq 1)
Figure imgf000014_0001
where C is the residual concentration of p-cresyl sulfate. Furthermore, the predicted adsorbed amount (Qm) could he calculated by Eq. 3 and Eq. 4,
o N U-iooo XM NU-ioao
Qr tϊ,NTί— 1000 0 (Eq 3)
Figure imgf000014_0002
_ Q.HSA XMHSA _
Qm.HSA (%)— X 100 (Eq. 4)
QN U-iooo xt'½ U-iooo + QHSAX1 HSA
where M is the mass of the adsorbent. FIG. 7 A shows the predicted removal fraction of y>-cresyl sulfate from HSA using MU- 1000. Herein, MHSA = 50 mg, MNU-IOOO = 2.5, 10, 20,
30 mg, C = 0.001 to 0.1 mM. The result predicted that 93% of p-cresyl sulfate could be removed by adding 20 mg of NU-I OOO To evaluate the reliability of the predicted -cresyi sulfate removal from HSA, 20 pg of p-crcsyl sulfate was mixed with 50 mg of HSA in 1.0 mL of an aqueous solution of 0.9 vol. % NaCl at 310 K. After keeping the solutions for 24 hours, 2.5, 10, 20, or 30 mg of NU-1000 was added to each solution and kept for a further 24 hours. After this competitive adsorption, the masses of unbound and HSA-bound p-crcsyl sulfate were measured by high performance liquid chromatography (HPLC). As shown in FIG. 7B, the fractions of HSA-bound and unbound p-crcsyl sulfate decreased upon increasing the mass of NU-1000. After adding 20 mg of NU-1000, 93% of p-crcsyl sulfate in the solution was removed by NU-1000, which is consistent with the predicted removal efficiency (93%). As shown in Table 4, the predicted values show a similar trend to this experimental competitive adsorption. These results demonstrate that the removal efficiency of uremic toxins by the MOFs can be estimated from adsorption isotherms of the adsorbate and the adsorbent.
Table 4. The predicted and measured competitive adsorption data
Amount of NU-1000
_ 2 5 mg 10 mg 20 mg 30mg
HSA-bound-predicted 35±2 l2±l 7±1 4±0.5
HSA-bound-measured 32 15 8 1
NU-l 000-bound- 65±2 88±1 93±1 96±0.5
predicted NU-l 000-bound- 57 88 93 99
measured
Experimental Section (Method)
Materials and General Experiments
[0050] All chemicals were used as received from the supplier. In these experiments, water is Milli-Q (Milli-pore). Indoxyl sulfate potassium salt was purchased from Alfa Assar and hippuric acid was purchased from Sigma Aldrich. Sigma Aldrich HPLC-GC grade (³99.8%) Acetonitrile and Strem chemicals potassium dihydrogen phosphate (KH2PO4) (99+%) were used for all HPLC experiments as a mobile phase.
[0051] UiO-66, UiO-67, UiO-NDC, PCN-6O8-OH, NU-901, NU-1000, NU-1200, and
MOF-808 were prepared according to literature procedures. (See, e.g., Katz, M. J., el al., Chem. Commun. 2013, 49, 9449-9451; Mondloch, J. E., et al, Nat Mater 2015 , 14 (5), 512-6; Pang, J., et al, J. Am. Chem. Soc. 2017, 139 (46), 16939-16945; Liu, T.-F., et al, Eur. J. Inorg. Chem. 2016, 27, 4349-4352; and Furukawa, H., et al, J Am Chem Soc 2014, 136 (11), 4369-81.)
[0052] Powder X-ray diffraction (PXRD) patterns were collected on an ATX-G (Rigaku) instrument equipped with an 18 kW copper rotating anode X-ray source. Roughly 3 mg of sample was loaded onto a sample holder and mounted on the instrument. Samples were recorded from 2° < Q < 20° at a scan rate of 27min and a step size of 0.05.
[0053] N2 sorption isotherms were collected on a Micromeretics Tristar II 3020 instrument at 77 K. Prior to the measurement, the samples were activated on a SmartVacPrep port by heating at the desired temperature under a vacuum overnight. Pore size distributions were calculated from the adsorption isotherms using the DFT method, based on a molecular statistical approach.
[0054] HPLC measurements were performed by an Agilent HPLC 1100 system equipped with a binary pump, a column thermostat, an auto sampler, and a diode-array absorbance detector (DAD), using an Ascentic C18 HPLC column (5 pm particle 150 mm><4.6 mm I.D.). A reverse phase HPLC assay of / cresyl sulfate was carried out using an isocratic elution with a flow rate of 1.0 mL/min, a column temperature of 40 °C, a mobile phase of acetonitrile and water (35: 65% v/v), and a detection wavelength of 230 nm. Assays of indoxyl sulfate and hippuric acid were performed using a mobile phase of 0.02 mM KΉ2RO4 and 0.002 mM l-pentasulfonic acid (pH 4.50), and a detection wavelength at 270 nm and 230 nm, respectively. For all experiments, 100 pL sample volumes were injected into the
chromatographic system.
[0055] SCXRD measurements were performed on a Bruker Kappa APEX II CCD equipped with a Cu Ka (l = 0.71073 A) IpS microsource with MX optics. A single crystal was mounted on MicroMesh (MiTeGen) with paratone oil. The structure was solved by direct methods (SHELXT-2014/5) and refined by full-matrix least-squares refinements on F2 (SHELXL-2017/1) using the Yadokari-XG software package. (See, e.g., Sheldrick, G., SHELX2017. Programs for crystal structure determination. Universitat Gottingen, Germany 2017; Kabuto, C. A., S., et al., J. Cryst. Soc. Jpn. 2009, 51, 218-224.) The disordered non- coordinated solvents were removed using the PLATON SQUEEZE program. (See, e.g., Spek, A., Acta Crystallogr. Sect. D. 2009, 65, 148-155.) The sulfate site locations and occupancies were determined by structural refinement. The associated CIF data file has been deposited in the Cambridge Crystallographic Data Centre (CCDC) under deposition numbers CCDC- 1868048 and 1868049. The data can be obtained free of charge via
www.ccdc.cam.ac.uk/data_request/cif (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.).
[0056] All DFT calculations were carried out in the Gaussian 16 package using the M06-L density functional and def2-SVP basis sets. (See, e.g., Frisch, M. J., et al., Gaussian 16 Rev. A.03, Wallingford, CT, 2016.) The SDD effective core potential was applied to the Zr atoms. The DFT-D3 dispersion correction with zero damping was applied.
Synthesis of NU-1010
[0057] The TCPB linker was synthesized according to literature procedures. (See, e.g., Pang, J., et al., J. Am. Chem. Soc. 2017, 139 (46), 16939-16945.) ZrCU (20 mg, 0.10 mmol) was dissolved in 3 mL dimethylformamide (DMF) and heated for lh at 80 °C, and subsequently trifluoroacetic acid (TFA) (100 pL, 1.31 mmol) was added and cooled down to room temperature before TCPB (10 mg, 0.059 mmol) was dissolved and sonicated for 15 min. The solution was heated at 120 °C for 48 hours. The white powder was washed three times with fresh DMF, acetone, and ethanol. The sample was activated by supercritical CO2 drying before being thermally activated in a vacuum oven at 80 °C for 18 hours.
Screening of /?-cresyl sulfate removal:
[0058] For initial screening experiments, the / cresyl sulfate removal by the Zre-based MOF materials UiO-66, UiO-67, UiO-NDC, PCN-6O8-OH, NU-1010, NU-901, NU-1000, NU-1200, and MOF-808 was investigated. In a typical experiment, 1.5 mg of each of the MOF samples was kept in contact with 2.5 mL of a 0.1 mM aqueous /i-crcsyl sulfate solution in a 1.5-dram glass vial. The solution was placed in the oven at 24 °C for 24 h to ensure saturation uptake was obtained. After 24 h, the samples were filtered off through a syringe filter (polyvinylidene difluoride (PVDF) membrane, 0.45 pm, Sartorius Minisart Syringe Filter). The initial and equilibrium concentrations of p-cresyl sulfate in each solution were measured using an Agilent HPLC 1100 system. The removal efficiency of the p-cresyl sulfate was calculated by using Eq. 5:
Removal (%) = Cl Cf x 100 (Eq. 5) where G = the initial concentration, and C/= the final concentration.
Adsorption site analysis
[0059] Single crystals of NU- 1000 were soaked in an aqueous /i-crcsyl sulfate solution (1.0 g L 1) at room temperature for 24 h and examined through SCXRD analysis. To determine the location of the adsorbed sulfate positions in the SCXRD analyses, the NU-1000 framework atoms were first located and refined, after which the residual electron densities were calculated. As shown in the Fo-Fc difference Fourier maps, the site positions of‘SOT of the sulfates were clearly observed and determined. However, the rest of the structure was difficult to model and refine due to the highly disordered nature of the aromatic ring parts and the high symmetry of the crystal. Therefore, to further determine the locations of these guest molecules, DFT calculations were conducted. In the second step, based on the SCXRD data, the geometry optimizations of >-cresyl and indoxyl sulfate were carried out in the Gaussian 16 package using the M06-L density functional and def2-SVP basis set. The positions of the framework atoms were taken from the experimental crystal structures and fixed during the optimizations. Proper truncations of the distant atoms were made to reduce the system size while keeping the entire system charge neutral. The proton topologies of the Zrc nodes were built according to a previous study. For the substrates, the positions of the sulfur atoms were also fixed to the experimental data, while the other atoms were added and allowed to move.
In the case of hippuric acid, the structure was built by replacing an adjacent pair of OH and OH2 groups on the node with the deprotonated hippuric acid through coordination between two Zr atoms and the carboxylate group. The geometry optimizations were performed as described above, with the entire hippuric acid not fixed and allowed to relax. Kinetic isotherm studies
[0060] To investigate the kinetics of uremic toxins as a function of time, kinetic studies were performed by exposing 6 mg of NU-1000 to 10 mL of a 0.1 mM aqueous uremic toxin solution, as well as / crcsyl sulfate, indoxyl sulfate and hippuric acid in 6-dram vials. The solution was placed in the oven at 24 °C oven. After predetermined times (1, 5, 15, 30, 60, and 240 min), 1.5 mL aliquots were taken by filtering with a 0.45 pm PVDF syringe filter. The removal efficiency as a function of time was measured by an HPLC system and calculated by Eq. 5 as well.
Adsorption isotherm studies (NU-1000)
[0061] Adsorption isotherm studies were conducted to calculate the maximum adsorption capacity of an adsorbent. These studies also give an understanding of the affinity of an adsorbent for target pollutants. Adsorption isotherms were constructed by exposing 1.5 mg of NU-1000 to 2.5 mL of an aqueous water solution (or 0.9% NaCl solution) to a designated concentration of uremic toxins in 1.5-dram vials. The solution was placed in the oven at a designated temperature (297, 303, 310 K) for 24 hours to reach saturation uptake. After 24 hours, the sample was filtered with a 0.45 pm PVDF filter syringe. The initial and equilibrium concentrations were measured by using an Agilent HPLC 1100, and the amount of uremic toxins uptake Q in mg of uremic toxins per gram of MOF was determined at each point according to Eq. 6:
Figure imgf000018_0001
where V = volume of solution exposed to NU-1000 (here, 10 mL), and m = mass of NU-1000 in grams (here, 6 mg).
[0062] All adsorption isotherms of uremic toxins adsorption on MOFs were described by either the Langmuir equation model or the Freundlich equation model, which are given in Eq. 7 and Eq. 8. The Langmuir equation gives the Langmuir equilibrium constant (AT) and adsorption capacity (Qe) for each uremic toxin.
KL xQmaxxC
Qe = 1+KLXC (Eq. 7)
Qe = KF X C1/" (Eq. 8) where Qe (mg g 1) = the amount adsorbed per unit mass of adsorbent at equilibrium, Qmax = the maximum uptake, C = the residual concentration of the adsorbate, n = the nonlinearity and adsorption intensities of the adsorbents.
Adsorption isotherm studies (HSA)
[0063] Adsorption isotherm studies were performed by exposing 50 mg of HSA to 1.0 mL of an aqueous 0.9% NaCl solution to a designated concentration of / crcsyl sulfate in 1.5-dram vials. The solution was placed in the oven at 310 K oven for 24 hours to reach saturation uptake. After 24 hours, the sample was filtrated and centrifuged at 1500 rpm for 15 min to allow the MOF to be settled by an ultrafiltration device (ultracel PL membrane, 30 Da, Millipore Sigma). The initial and equilibrium concentrations were measured by using an Agilent HPLC 1100, and the amount of uremic toxins uptake Q in mg of uremic toxins per gram of MOF was determined at each point, according to previous studies of uremic toxins.
/i-cresyl sulfate removal from HSA (competitive adsorption)
[0064] Competitive adsorption studies were performed in which 50 mg of HSA was added to 1 mL of a 20 pg mL 1 aqueous / cresyl sulfate solution in a 2-dram vials. The solution was placed in the oven at 310 K for 24 hours ensure it reached saturation uptake, and a designated amount of NU-1000 was added to this solution and kept in the oven. After 24 hours, the sample was separated into two parts. One part was filtrated and centrifuged at 1500 rpm for 15 min by an ultrafiltration device (ultracel PL membrane, 30 kDa, Millipore Sigma). The other part was heated at 100 °C for 5 min and centrifuged at 5000 rpm for 5 min. The aliquot was filtered using a 0.45 pm PVDF filter syringe. The concentrations of the samples were measured by HPLC as well.
Recyclability test
[0065] Facile regeneration of an adsorbent is very important not only for its
environmental sustainability but also for its commercial feasibility. To recover the NU-1000 after adsorption, NU-1000 could be activated with a 0.5 mM HC1/DMF solution for 10 hours at 80 °C, followed by a water wash (10 mL c 5 times), and the regenerated NU-1000 could be reused for the next adsorption. These adsorption-desorption cycles can be successfully repeated three times, and the same high removal efficiency by the regenerated NU-1000 can be obtained up to three times (FIG. 14).
Example 2 [0066] Example 1 describes the efficient removal of PBUTs by NU-1000, an 8-connected MOF consisting of Zre-nodes and tetratopic pyrene-based linkers.
[0067] This Example describes the use of ITC to identify the type and quantify the thermodynamic parameters of adsorptive interactions between PBUTs, namely p-CS and IS, and mesoporous Zr-based MOFs.
[0068] Preliminary ITC experiments investigated the energetics of p-CS and IS adsorbing onto NU-1000 in Tris-HCl buffer at pH 7.4 (FIG. 16 panels (a) - (d), Table 5, and Table 6). Prior to conducting the ITC measurements, PXRD and N2 adsorption isotherms confirmed that NU-1000 retained its structural integrity even when immersed in Tris-HCl buffer at pH 7.4 for one week. Negative peaks in the ITC thermograms of p-CS and IS binding to NU- 1000 at 25 °C indicated that the adsorption processes proceeded exothermically (FIG. 16 panels (a) - (d)). Fitting the ITC thermograms using a single site adsorption model yielded the lowest errors (<10%) in all experiments.
Table 5. Thermodynamic parameters of uremic toxins adsorbing onto NU-1000
Uremic Temp T A S (kcal mol D G (kcal mol
Ka (104, M-1) AH (kcal mol·1)
toxin (°C) "
p-CS 25 0.41 ± 0.10 1.03 ± 0.02 -4.18 ± 0.40 1.29 ± 0.40 -5.47 ± 0.01
30 0.38 ± 0.10 0.80 ± 0.14 -4.33 ± 0.28 1.07 ± 0.22 -5.39 ± 0.11
37 0.40 ± 0.05 0.51 ± 0.05 -4.25 ± 0.46 1.00 ± 0.5 -5.25 ± 0.06
IS 25 0.37 ± 0.03 0.97 ± 0.16 -2.53 ± 0.28 2.89 ± 0.38 -5.42 ± 0.10
30 0.34 ± 0.04 1.20 ± 0.24 -2.16 ± 0.17 3.46 ± 0.20 -5.62 ± 0.08
37 0.36 ± 0.09 1.21 ± 0.33 -1.64 ± 0.46 4.05 ± 0.54 -5.69 ± 0.13
Table 6. ITC measurement conditions.
_ MOF _ NU-1000 _ NU- 1010 _ PCN-608-QH
Uremic toxin pCS IS pCS IS pCS IS Concentration of cell 0.4 0.4 0.4 0.4 0.4 0.4 (mM)*
Concentration of syringe 4 4 4 4 4 4 (mM)
The number of injections 58 58 29 29 29 29 Injection volume (mΐ) 5 5 10 10 10 10 Duration of each 10 10 20 20 20 20 injections (sec) Spacing between 500 500 500 500 500 500 injections (sec)
Filter period (sec) 10 10 10 10 10 10
[0069] To evaluate the performance of NU- 1000 as a sorbent for p-CS,p-CS adsorbing onto HSA was also examined. NU-1000 displayed a higher binding affinity (Ka =1.03 ± 0.02 x 104 M 1) for p- CS and a larger change in Gibbs free energy upon adsorption of p- CS compared to HSA (Ka = 0.69 ± 0.07 c 104 M 1) (FIG. 17, panels (a) - (d) and Table 7). Conversely, NU-1000 exhibited positive values of TAS for p- CS adsorption, which contributed to the large Gibbs free energy change (AG). The disorder, and thereby the entropy, of the system increases when water and buffer molecules are released from the Zre- nodes upon binding of p- CS. Therefore, both enthalpy (i.e. hydrogen bonding) and entropy (hydrophobic interactions) govern the adsorption of p- CS on NU-1000. These
thermodynamic data corresponded well to the previously observed SCXRD data, which revealed hydrogen bonding interactions between p- CS and hydroxyl ligands on the Zre-nodes of NU-1000 and p-p stacking (hydrophobic interactions) between p- CS and the framework’s pyrene linkers.
Table 7. Thermodynamic parameters of uremic toxins adsorbing onto HSA.
Uremic Temp 4 AH (kcal 7A,S'(kcal AG (kcal toxin (°C) _ n_ _ a ’ mol 1) _ mol 1) _ mol 1) pCS 25 1.27 ± 0.16 0.69 ± 0.07 -6.08 ± 0.15 -0.84 ± 0.21 -5.23 ± 0.06
30 1.36 ± 0.13 0.52 ± 0.01 -5.77 ± 0.34 -0.61 ± 0.35 -5.16 ± 0.01
_ 37 1 48 ± 0 16 0 40 ± 0 01 -5 37 ± 0 34 -0 30 ± 0 39 -5 07 ± 0 05
IS 25 0.93 ± 0.01 6.16 ± 0.01 -8.96 ± 0.05 -2.42 ± 0.05 -6.54 ± 0.01
30 0.86 ± 0.03 5.53 ± 0.17 -8.88 ± 0.42 -2.30 ± 0.40 -6.58 ± 0.02
37 0.88 ± 0.01 3.91 ± 0.05 -9.22 ± 0.06 -2.70 ± 0.06 -6.52 ± 0.01
[0070] The interactions between /;-CS and the Zr6-nodes of NU- 1000 were further interrogated by collecting ITC thermograms in different buffer solutions. Prior to any ITC experiments, it was confirmed that NU-1000 retained its structural integrity even after being immersed in the respective buffers for one week. If p- CS coordinates to the Zre-nodes through a pseudo-ion-exchange process, then the enthalpy of adsorption ( AH) would be expected to depend on the buffer’s ionization enthalpy (DH ionization). Conversely, initial studies confirmed p- CS adsorbs predominantly through hydrogen bonding and hydrophobic interactions; therefore, the adsorption enthalpy would be anticipated to be independent of the buffer. In the ADA buffer, which displays the second lowest A Hiomzation of all buffers studied, the adsorption enthalpy possessed the largest magnitude. Moreover, the A H did not correlate with the buffers’ A Hiomzation values (FIGS. 18A and 18B, Table 8). Therefore, it can be confirmed that no ion-exchange reactions occur between p- CS and NU-1000 under these conditions. Importantly, ITC thermograms collected in various buffers display similar association constants (Ka) and entropy and enthalpy compensation. Therefore, when comparing different MOFs, the p- CS binding affinities should be comparable even in different buffers; however, to determine the contributions of entropy and enthalpy to the overall Gibbs free energy change, the same buffer should be employed.
Table 8. Thermodynamic parameters of p- CS adsorbing onto NU-1000 in different buffers.
TAS AG
Ka AH
Buffer pKa AH ionization fl , (kcal (kcal
(104, M 1) (kcal mol
mol-1) mol-1)
Tris- 1.00 ± -3.86 ± 1.60 ± -5.46 ±
8.00 11.36 0.35 ± 0.02
HC1 0.05 0.10 0.10 0.02
1.21 ± -1.59 ± 3.96 ± -5.55 ±
ACES 6.75 7.51 0.22 ± 0.01
0.05 0.10 0.09 0.03
1.06 ± -1.01 ± 4.47 ± -5.48 ±
MOPS 7.09 5.21 0.12 ± 0.02
0.01 0.05 0.05 0.04
1.27 ± -6.00 ± -0.40 ± -5.40 ±
ADA 6.76 2.90 0.17 ± 0.03
0.05 0.24 0.30 0.04
1.29 ± -3.40 ± 2.20 ± -5.40 ±
PIPES 6.71 2.74 0.06 ± 0.01
0.01 0.16 0.30 0.02
[0071] Compared to p- CS adsorption on NU-1000, indoxyl sulfate displayed a higher binding affinity (Ka = 1.27 ± 0.01 c 104 M_1) and a larger entropy contribution to the overall Gibbs free energy change (TAS = 3.18 kcal mol 1). This result is consistent with the aforementioned SCXRD analysis and DFT calculations, which predicted indoxyl sulfate could interact strongly with the pyrene linkers of NU-1000. Upon increasing the reaction temperature, the binding affinity (Ka) of p- CS adsorbing onto NU-1000 decreased from 1.03 to 0.51 x 104 M 1; however, the binding affinity of indoxyl sulfate adsorbing onto NU-1000 remained constant at -1.0 c 104 M 1 (FIG. 19). The entropy change associated with p- CS adsorption also decreased with increasing temperature from 1.29 kcal mol 1 to 0.99 kcal mol likely due to a weakening of p-p interactions between p- CS and the pyrene linkers of NU- 1000. Conversely, the entropy of indoxyl sulfate increased from 3.59 kcal mol 1 to 4.71 kcal mol 1 upon increasing the reaction temperature. This likely resulted from strong p-p interactions between indole and the pyrene linker of NU- 1000. These results demonstrate that linker hydrophobicity is an important factor governing the adsorption of uremic toxins on MOFs. When adsorbing onto HSA, the Ka of both uremic toxins decreased with increasing temperature because these processes are enthalpically driven (FIG. 20).
[0072] Example 1 reported two crystallographically distinct uremic toxin adsorption sites in NU-lOOO, Site 1 and Site 2. Specifically, in the large hexagonal mesopore (Site 1 ). / -CS sits perpendicular to the linker’s pyrene core while interacting with the phenyl substituent of one of the linker’s arms. While in the triangular small pore (Site 2), p-CS lies parallel to the pyrene region and interacts with two neighboring pyrene linkers. These observations led to the questioning of which site interacted more strongly. To clarify the energetics of interactions, the thermodynamic parameters of p-CS adsorption onto two MOFs with identical topology and similar pore size and shape to NU-1000 but with different linkers were examined. Specifically, NU-1010 and PCN-608-OH possess tetratopic linkers based on biphenyl and dihydroxybiphenyl rather than pyrene. ITC thermograms for p-CS adsorption onto PCN-608-OH did not show any enthalpy peaks, indicating that the pyrene ligand plays a vital role in adsorptive interactions at Site 2 (FIG. 21, panels (a) - (d)). Comparatively, adsorption of p-CS onto NU-1000 displayed larger exothermic AH peaks than the adsorption process onto NU-1010; however, the Gibbs free energy for both processes were nearly identical (FIGS. 22A and 22B, Table 9). These thermodynamic parameters show that adsorption at Site 1 is entropically driven and due to hydrophobic interaction; the large increase in entropy compensates for the much smaller enthalpy change in the overall Gibbs free energy change. Alternatively, adsorption at Site 2 is both entropically and enthalpically driven, arising from hydrophobic interactions and p-p interactions with the pyrene moiety of the linker.
Table 9. Thermodynamic parameters for the adsorption of uremic toxins onto NU-1010
Uremic MOF n Ka (104, Atf (kcal TAS (kcal AG (kcal toxin mol 1) mol 1) mol 1) pCS NU-1000 0.41 ± 1.03 ± 0.02 -4.18 ± 0.40 1.29 ± 0.40 -5.47 ± 0.01
0.10
NU-1010 0.25 ± 0.71 ± 0.02 -0.77 ± 0.02 4.51 ± 0.04 -5.28 ± 0.03
_ 002 _
IS NU-1000 0.37 ± 0.97 ± 0.16 -2.53 ± 0.28 2.89 ± 0.38 -5.42 ± 0.10
0.03
NU-1010 0.68 ± 0.75 ± 0.07 -0.09 ± 0.02 5.19 ± 0.07 -5.28 ± 0.05
0.20 [0073] In summary, the energetics of interactions between uremic toxins and MOFs were explored using ITC. The thermodynamic parameters obtained from the ITC thermograms suggested that the interactions between uremic toxins and NU-1000 are both enthalpically and entropically driven. Drawing from XRD studies and ITC experiments using an assortment of MOFs with esq topology, two distinct adsorption sites in NU-1000 were delineated; one in the mesopore, at which interactions are primarily entropically driven (Site 1), and one in the small triangular micropore, at which interactions are both entropically and enthalpically driven (Site 2).
Materials and methods
[0074] All chemicals were used as received from the supplier. In these experiments, all water was Milli-Q (Millipore). Potassium /;-cresyl sulfate was purchased from Enamine and potassium indoxyl sulfate was purchased from Alfa Aesar. Ultrapure™ 1 M Tris-HCl Buffer (pH 7.5) was purchased from ThermoFisher scientific (Invitrogen™). NU-1000, NU-1010, and PCN-608-OH were prepared according to literature procedures (see below). PXRD patterns were collected on an STOE-STADI-MP instrument equipped with an asymmetric curbed Germanium monochromator (CuKal radiation, l = 1.54056 A). Roughly 3 mg of sample was loaded onto a sample holder and mounted on the instrument. Samples were recorded from 1 °<()< 40° at a scan rate of 27min and a step size of 0.10°. N2 sorption isotherms were collected on a Micromeritics Tristar II 3020 instrument at 77 K. Prior to each measurement, samples were thermally activated on a Smart VacPrep under ultrahigh vacuum. DFT-calculated pore size distributions were calculated using a carbon slit-pore model with a kernel, based on a molecular statistical approach.
[0075] ITC experiments were performed using a VP-ITC titration microcalorimeter (MicroCal Inc.). Prior to the titration experiment, MOF and HSA samples were dialyzed in a 50 mM Tris-HCl buffer solution (ion strength = 0.15M) using a Slide-A-Lyzer™ MINI Dialysis Device for 24 hours. Solutions of p-CS and IS were filtrated off through a syringe filter (PVDF membrane, 0.45 pm, Satorious Minisart Syringe Filter). All samples were degassed properly on a vacuum pump for 20 mins. Titrations were performed by injecting a solution of p-CS or IS into the ITC sample cell containing MOF suspensions or HSA solutions. All titrations were carried out at pH 7.4 ± 0.1 in aqueous buffer solutions under the following measurement conditions: reference power (10 peal s 1), initial injection delay (600 s), stirring speed (307 rpm), feedback mode gain (high feedback), spacing between injections (500 s), and filter period (10 s). All other conditions are described in Table 6. All titration experiments were performed in triplicate. A thermodynamic profile of each binding interaction was determined by fitting the data with a single-site interaction model. Heats of dilution for uremic toxins were determined in control experiments, and these were subtracted from the integrated data before curve fitting.
MOF Syntheses
[0076] Synthesis of NU-1000. 4, 4', 4' ',4' ' '-(pyrene-l,3,6,8-tetrayl)tetrabenzoate
(H-iTBAPy) was synthesized according to literature procedure. (Islamoglu, T. et al.,
CrystEngComm 2018, 20, 5913-5918.) ZrOCh · 8H2O (200 mg, 0.618 mmol) and benzoic acid (4.00 g, 0.033 mol) were dissolved in 16 mL of DMF and heated for 1 h in a preheated oven at 80 °C. After cooling down to room temperature, TFA (160 pL, 2.09 mmol) was added and cooled down to room temperature before FLTBAPy (80 mg, 0.117 mmol) was dissolved and sonicated for 15 min. The solution was heated at 100 °C for 24 h. After cooling down to room temperature, yellow material was isolated by centrifuge (10 min, 1000 RCF) and washed with fresh DMF (15 mL each, three times) (soaked ~l h between washes). The resulting yellow powder was suspended in 24 mL DMF, and 1.0 mL of 12 M aqueous HC1 was added. The mixture was heated in an oven at 100 °C for 18 h. After cooling to room temperature, the powder was washed with fresh DMF (15 mL each, three times) and acetone (15 mL each, three times) (soaked ~l h between washes) and soaked in acetone for additional 18 h. NU-1000 crystals were collected by centrifugation and dried in an oven at 80 °C for 5 h, and then thermally activated on a Smart VacPrep under ultrahigh vacuum at 100 °C for 24 h.
[0077] Synthesis of NU-1010. 3,3',5,5'-tetrakis(4-carboxyphenyl)-l,l'-biphenyl (TPCB) linker was synthesized according to literature procedure. (Pang, J. et al, J. Am. Chem. Soc. 2017, 139, 16939-16945.) ZrCk (20 mg, 0.10 mmol) was dissolved in 3 mL of DMF and heated for 1 h in a preheated oven at 80 °C. After cooling down to room temperature, TFA (100 pL, 1.31 mmol) was added and cooled down to room temperature before TPCB (10 mg, 0.016 mmol) was dissolved and sonicated for 15 min. The solution was heated at 120 °C for 72 h. After cooling down to room temperature, white material was isolated by centrifugation (10 min, 1000 RCF) and washed with fresh DMF (15 mL each, three times) (soaked ~l h between washes). The resulting white powder was suspended in 10 mL DMF and 0.3 mL of 12 M aqueous HC1 was added. The mixture was heated in an oven at 100 °C for 18 h. The white powder was washed with fresh DMF (15 mL each, three times), acetone (15 mL each, three times) and ethanol (15 mL each, three times). The sample was activated by supercritical CO2 drying before being thermally activated on a Smart VacPrep under ultrahigh vacuum at 80 °C for 18 h.
[0078] Synthesis of PCN-6O8-OH. TPCB-OH linker was synthesized according to literature procedure. (Pang, et al., 2017.) ZrCL (20 mg, 0.10 mmol) was dissolved in 2.5 mL DMF and heated for 1 h in a preheated oven at 80 °C, and subsequently TFA (100 pL, 1.31 mmol) was added and cooled down to room temperature before TPCB-OH (10 mg, 0.015 mmol) was dissolved and sonicated for 15 min. The solution was heated at 120 °C for 72 h. After cooling down to room temperature, the material was isolated by centrifugation (10 min, 1000 RCF) and washed with fresh DMF (15 mL each, three times) (soaked ~l h between washes). The resulting powder was suspended in 10 mL DMF, and 0.3 mL of 12 M aqueous HC1 was added. The powder was washed with fresh DMF (15 mL each, three times), acetone (15 mL each, three times), and ethanol (15 mL each, three times). The sample was thermally activated on a Smart VacPrep under ultrahigh vacuum at 80 °C for 18 h.
Theory of isothermal titration calorimetry
[0079] ITC has been widely used for studying enzymatic systems but it should also be applicable to MOF systems. In this section, the theory of ITC and the mathematical formulation behind it is briefly explained. Following the framework described in Lawrence Indyk et al., the binding of a single ligand, L (sulfate anion in this study), with a MOF receptor, M (MOF crystals in this study), can be considered (Indyk, L. et al., Methods Enzymol. 1998, 295, 350-364.):
[M] + n[L] n[ML] (Eq. 9)
[M] + [L] ¹ [ML] (Eq. 10) where ML is the ligand-bound MOF complex. The binding stoichiometry is given by n. Only single-site independent binding and one-to-one binding were considered in this case (n=l, Eq. 10). MOF crystals, especially NU-1000, should have several binding sites, but each site is thermodynamically identical and has similar affinity for sulfate ions. The equilibrium association constant, Ka. is defined as
Figure imgf000026_0001
(Eq. 11) where the terms in brackets represent the equilibrium concentrations of the respective species. ML represents the MOF node with ligands (sulfate anion) bound to it. The expressions for the equilibrium constants (S) can be combined with mass balances on each component:
[MT] = [M] + [ML] (Eq. 12) and
\LT] = [L] + [ML] (Eq. 13)
[0080] Eqs. 12 and 13 can be extended to any binding system of ligands, noting that [MT] and [LT] are the total concentrations of MOF and ligand in the calorimeter cell. These variables are used because they are the known quantities in an experiment, and it would be useful to solve for some of the unknown quantities, such as [M] and [L] in terms of these two. The dependent variable in ITC experiments is the total amount of heat released per injection of ligand, dQ:
Figure imgf000027_0001
(Eq. 14) where V is the volume of the calorimetric cell, AH is the enthalpy of binding for formation of [ML] Substituting Eqs. 11-13 into Eq. 14 allows AQ to be written explicitly in terms of Ka. AH, [M T], and [L T] . The integrated heats from each injection can be fit to a model as a function of molar ratio to determine heat from the standard parameters (Ka, AH, and ri) in a single experiment. The value of AG is determined from the standard thermodynamic definition, AG = -KUn(Ka), and the entropy of adsorption, AS, is calculated from AG =AH - T AS.
[0081] The full form of Eq. 15 for independent binding used to fit the integrated heat data from ITC is given as:
Figure imgf000027_0002
(Eq. 15)
[0082] The word "illustrative" is used herein to mean serving as an example, instance, or illustration. Any aspect or design described herein as "illustrative" is not necessarily to be construed as preferred or advantageous over other aspects or designs. Further, for the purposes of this disclosure and unless otherwise specified, "a" or "an" means "one or more.”
[0083] The foregoing description of illustrative embodiments of the invention has been presented for purposes of illustration and of description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and modifications and variations are possible in light of the above teachings or may be acquired from practice of the invention. The embodiments were chosen and described in order to explain the principles of the invention and as practical applications of the invention to enable one skilled in the art to utilize the invention in various embodiments and with various modifications as suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims

WHAT IS CLAIMED IS:
1. A method for removing uremic toxins from a sample, the method comprising: exposing a sample comprising protein-bound uremic toxins to a metal -organic framework, the metal-organic framework comprising a plurality of metal nodes connected by pyrene group-containing organic linkers, wherein the protein-bound uremic toxins are adsorbed by the metal-organic framework; and
removing the metal-organic framework compound and the adsorbed protein-bound uremic toxins from the sample.
2. The method of claim 1, wherein the metal -organic framework comprises Zr6 nodes.
3. The method of claim 2, wherein the metal -organic framework has hydroxyl groups on the metal nodes.
4. The method of claim 1, wherein the metal -organic framework has hydroxyl groups on the metal nodes.
5. The method of claim 2, wherein the metal -organic framework comprises Zr6 nodes connected by tetratopic 4,4',4'',4'"-(pyrene-l,3,6,8-tetrayl)tetrabenzoic acid organic linkers and has a esq network topology.
6. The method of claim 2, wherein the metal-organic framework comprises Zr6 nodes connected by tetratopic 4,4',4'',4'"-(pyrene-l,3,6,8-tetrayl)tetrabenzoic acid organic linkers and has a sen network topology.
7. The method of claim 1, wherein the protein-bound uremic toxins comprise sulfate compounds, carboxylic acid compounds, or a mixture thereof.
8. The method of claim 7, wherein the protein-bound uremic toxins comprise p- cresyl sulfate, indoxyl sulfate, hippuric acid, or a mixture thereof.
9. The method of claim 1, wherein the sample comprises blood serum.
10. The method of claim 1, wherein the metal -organic framework comprises Tΰ¾ nodes, Ce6 nodes, or Th6 nodes
11. A metal-organic framework comprising Zre nodes, Tΰ¾ nodes, Ce6 nodes, or The nodes connected by tetratopic 3,3',5,5'-tetrakis(4-carboxyphenyl)-l,l'-biphenyl linkers and having a esq network topology.
12. The metal-organic framework of claim 11, comprising the Zr6 nodes.
13. A method for removing uremic toxins from a sample, the method comprising: exposing a sample comprising protein-bound uremic toxins to a metal -organic framework, the metal-organic framework Zr6 nodes, Tΰ¾ nodes, Ce6 nodes, or Th6 nodes connected by tetratopic 3,3',5,5'-tetrakis(4-carboxyphenyl)-l,l'-biphenyl linkers and having a esq network topology, wherein the protein-bound uremic toxins are adsorbed by the metal- organic framework; and
removing the metal-organic framework compound and the adsorbed protein-bound uremic toxins from the sample.
14. The method of claim 13, wherein the metal-organic framework comprises the Zr6 nodes.
PCT/US2019/057302 2018-10-23 2019-10-22 Metal-organic frameworks for the removal of uremic toxins Ceased WO2020086496A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/286,986 US12403412B2 (en) 2018-10-23 2019-10-22 Metal-organic frameworks for the removal of uremic toxins
US19/289,512 US20250360434A1 (en) 2018-10-23 2025-08-04 Metal-organic frameworks for the removal of uremic toxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862749353P 2018-10-23 2018-10-23
US62/749,353 2018-10-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/286,986 A-371-Of-International US12403412B2 (en) 2018-10-23 2019-10-22 Metal-organic frameworks for the removal of uremic toxins
US19/289,512 Continuation US20250360434A1 (en) 2018-10-23 2025-08-04 Metal-organic frameworks for the removal of uremic toxins

Publications (1)

Publication Number Publication Date
WO2020086496A1 true WO2020086496A1 (en) 2020-04-30

Family

ID=70332154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/057302 Ceased WO2020086496A1 (en) 2018-10-23 2019-10-22 Metal-organic frameworks for the removal of uremic toxins

Country Status (2)

Country Link
US (2) US12403412B2 (en)
WO (1) WO2020086496A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022014122A1 (en) * 2020-07-13 2022-01-20
US20220339601A1 (en) * 2021-04-26 2022-10-27 Colorado State University Research Foundation METAL-ORGANIC FRAMEWORKS FOR p-Cresyl SULFATE ADSORPTION

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118837427B (en) * 2024-04-11 2026-08-11 宁波大学 Porous material, application thereof, preparation method and detection method
CN118122285B (en) * 2024-04-12 2026-05-01 中国计量大学 Preparation method of multi-metal organic framework modified graphene oxide microsphere

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130240361A1 (en) * 2010-11-02 2013-09-19 Icinnovation Bv Electrosorption and decomposition device for the purification of blood and other fluids
US20150290381A1 (en) * 2013-12-20 2015-10-15 Nephrogenesis Llc Methods and apparatus for kidney dialysis and extracorporeal detoxification
US20170096394A1 (en) * 2014-05-26 2017-04-06 Mohamed Eddaoudi Design, synthesis and characterization of metal organic frameworks
US20170362167A1 (en) * 2014-11-20 2017-12-21 Northwestern University Zirconium- and hafnium-based metal-organic frameworks as epoxide ring-opening catalysts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130240361A1 (en) * 2010-11-02 2013-09-19 Icinnovation Bv Electrosorption and decomposition device for the purification of blood and other fluids
US20150290381A1 (en) * 2013-12-20 2015-10-15 Nephrogenesis Llc Methods and apparatus for kidney dialysis and extracorporeal detoxification
US20170096394A1 (en) * 2014-05-26 2017-04-06 Mohamed Eddaoudi Design, synthesis and characterization of metal organic frameworks
US20170362167A1 (en) * 2014-11-20 2017-12-21 Northwestern University Zirconium- and hafnium-based metal-organic frameworks as epoxide ring-opening catalysts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATO ET AL.: "Zirconium-Based Metal-Organic Frameworks for the Removal of Protein-Bound Uremic Toxin from Human Serum Albumin", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 141, no. 6, 1 February 2019 (2019-02-01) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022014122A1 (en) * 2020-07-13 2022-01-20
EP4180048A4 (en) * 2020-07-13 2024-07-10 Applause Pharma Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A CERIUM COMPOUND AS ACTIVE INGREDIENT
US12472206B2 (en) 2020-07-13 2025-11-18 Applause Pharma Co., Ltd. Pharmaceutical composition containing cerium compound as active ingredient
US20220339601A1 (en) * 2021-04-26 2022-10-27 Colorado State University Research Foundation METAL-ORGANIC FRAMEWORKS FOR p-Cresyl SULFATE ADSORPTION

Also Published As

Publication number Publication date
US12403412B2 (en) 2025-09-02
US20250360434A1 (en) 2025-11-27
US20210387110A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
US20250360434A1 (en) Metal-organic frameworks for the removal of uremic toxins
Xia et al. Tetracycline removal from aqueous solution using zirconium-based metal-organic frameworks (Zr-MOFs) with different pore size and topology: Adsorption isotherm, kinetic and mechanism studies
Cheng et al. Clearance of low molecular-weight uremic toxins p-cresol, creatinine, and urea from simulated serum by adsorption
Wang et al. Cationic covalent organic framework for efficient removal of PFOA substitutes from aqueous solution
Chen et al. Facile preparation of core–shell magnetic metal–organic framework nanoparticles for the selective capture of phosphopeptides
Benzaqui et al. Revisiting the aluminum trimesate-based MOF (MIL-96): from structure determination to the processing of mixed matrix membranes for CO2 capture
Lin et al. Construction of a polyhedral metal–organic framework via a flexible octacarboxylate ligand for gas adsorption and separation
Paz et al. Zirconium-organic framework as a novel adsorbent for arsenate remediation from aqueous solutions
Dai et al. Cationic ionic liquids organic ligands based metal–organic frameworks for fabrication of core–shell microspheres for hydrophilic interaction liquid chromatography
Cuchiaro et al. Exploring the parameter space of p-Cresyl sulfate adsorption in metal–organic frameworks
Maya et al. Emerging materials for sample preparation
Li et al. MOF-based antibiofouling hemoadsorbent for highly efficient removal of protein-bound bilirubin
JP7365651B2 (en) Calciprotein particle adsorbent, adsorption removal system and its usage
Tetala et al. A metal ion charged mixed matrix membrane for selective adsorption of hemoglobin
Zheng et al. Engineering magnetic guanidyl-functionalized supramolecular organic framework for efficient enrichment of global phosphopeptides
Kundu et al. Salt metathesis in three dimensional metal–organic frameworks (MOFs) with unprecedented hydrolytic regenerability
Chen et al. Ibuprofen loaded into metal–organic framework shells coated on Fe3O4 nanoparticles for the removal of protein-bound uremic toxins in blood
Zhang et al. Reticular access to triptycene-based cationic metal–organic frameworks for protein-bound uremic toxins sorption
US11331597B2 (en) Cation exchange materials for dialysis systems
He et al. Preparation of a novel Zr4+-immobilized metal affinity membrane for selective adsorption of phosphoprotein
CN101279243B (en) A mixed mode expanded adsorption bed medium and its preparation method
Desai et al. Specific recognition of toxic allyl alcohol by pore-functionalized metal–organic frameworks
Zhang et al. Clearance of protein-bound uremic toxins using anion nanotraps with record high uptake
Alqarni et al. ZIFs-MOF anchored amberlite polymer for uses as an adsorbent in a hemodialysis
WO2024097706A1 (en) System for removing protein bound uremic toxins during hemodialysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19874862

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19874862

Country of ref document: EP

Kind code of ref document: A1

WWG Wipo information: grant in national office

Ref document number: 17286986

Country of ref document: US